NFKB1 and pulmonary fibrosis: Unsurprisingly, various therapeutic strategies targeted at the NF-κB signaling pathway, including NF-κB–specific decoy oligonucleotide, p65-specific antisense oligonucleotide, and IKKβ-selective small molecule inhibitor have suggested positive effects in the pulmonary fibrosis and pulmonary inflammation associated disorders, including IPF, chronic obstructive pulmonary disease (COPD), acute lung injury/acute respiratory distress syndrome (ALI/ARDS), and asthma [20,33].